Charles River Laboratories stock slips 1.97%, ending two-day winning streak
Updated
Updated · MarketWatch · May 6
Charles River Laboratories stock slips 1.97%, ending two-day winning streak
5 articles · Updated · MarketWatch · May 6
Shares closed at $181.73 on Wednesday, even as the S&P 500 rose 1.46% to 7,365.12 and the Dow gained 1.24% to 49,910.59.
The stock underperformed in a broadly positive market session and remained 20.60% below its 52-week high of $228.88 reached on 13 January.
Against peers, Labcorp edged down 0.08%, Alnylam Pharmaceuticals rose 0.63%, and Bio-Techne dropped 16.36%, leaving Charles River's performance mixed relative to competitors.
With analysts predicting a 28% upside, why does the market keep punishing Charles River Labs stock?
What separates winners from losers in the life sciences sector as their stock performances diverge so sharply?
Is Charles River Labs' strategy a smart focus or a dangerous bet against AI disruption?